Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Hillstream BioPharma, a biotechnology company specializing in the development of innovative treatments for drug-resistant cancers, has recently announced a strategic reprioritization of its pipeline. The focus will now shift towards targeting HER2/HER3 solid tumors using bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs). &nbsp The company's lead bispecific antibody, HSB-3215, is ..